Patents by Inventor Thomas R. Spitzer

Thomas R. Spitzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of hematologic disorders
    Patent number: 7892578
    Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: February 22, 2011
    Assignee: The General Hospital Corporation
    Inventors: Megan Sykes, Thomas R. Spitzer
  • Treatment of Hematologic Disorders
    Publication number: 20090028870
    Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
    Type: Application
    Filed: August 4, 2008
    Publication date: January 29, 2009
    Inventors: Megan Sykes, Thomas R. Spitzer
  • Kits for treatment of hematologic disorders
    Patent number: 7408039
    Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: August 5, 2008
    Assignee: The General Hospital Corporation
    Inventors: Megan Sykes, Thomas R. Spitzer
  • Treatment of hematologic disorders
    Publication number: 20030157077
    Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
    Type: Application
    Filed: February 25, 2003
    Publication date: August 21, 2003
    Inventors: Megan Sykes, Thomas R. Spitzer
  • Treatment of hematologic disorders
    Patent number: 6558662
    Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: May 6, 2003
    Assignee: The General Hospital Corporation
    Inventors: Megan Sykes, Thomas R. Spitzer
  • TREATMENT OF HEMATOLOGIC DISORDERS
    Publication number: 20010048921
    Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
    Type: Application
    Filed: November 13, 1998
    Publication date: December 6, 2001
    Applicant: The General Hospital Corporation
    Inventors: MEGAN SYKES, THOMAS R. SPITZER